



Cytokinetics to Host Investor Event on December 13, 2010

December 9, 2010 12:32 PM EST

Panel to Discuss the Results of the Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis

SOUTH SAN FRANCISCO, CA, Dec 09, 2010 (MARKETWIRE via COMTEX) --

Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company is scheduled to host an Investor Event entitled "Perspectives on the Phase IIa Clinical Trial Data of CK-2017357 in Patients with ALS" on Monday, December 13, 2010 from 7:00 a.m. - 8:00 a.m. Eastern Standard Time in the Del Lago 4 Room at the JW Marriott Grande Lakes Hotel in Orlando, Florida.

At this meeting, Robert Blum, Cytokinetics' President and Chief Executive Officer, is scheduled to be joined by members of Cytokinetics' management team and key opinion leaders in the ALS field, including Robert G. Miller, M.D., Clinical Professor of Neurology and Neurological Sciences at Stanford University, and Director of the Forbes Norris ALS Research Center at the California Pacific Medical Center, and Jeremy M. Shefner, M.D., Ph.D., Professor and Chair of the Department of Neurology at the Upstate Medical University at the State University of New York, who served as the Principal Investigator in this clinical trial.

The presentation and accompanying slides will be simultaneously webcast beginning at 7:00 a.m. Eastern Standard Time and can be accessed through the Investor Relations section of the Cytokinetics' website at www.cytokinetics.com. The live audio of the forum will also be accessible via telephone by dialing either (866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078 (international) and typing in the passcode 28990049. Those wishing to attend this event in person should RSVP to investor@cytokinetics.com by the morning of Friday, December 10, 2010.

An archived replay of the webcast will be available on the Presentations page in the Investors Center section of Cytokinetics' website until January 14, 2011. The replay will also be available via telephone from December 13, 2010 at 10:00 a.m. Eastern Standard Time until December 20, 2010 by dialing (800) 642-1687 (United States and Canada) or (706) 645-9291 (international) and typing in the passcode 28990049.

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil (formerly CK-1827452), is in clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing CK-2017357, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. CK-2017357 is currently the subject of a Phase IIa clinical trials program and has been granted orphan-drug designation by the U.S. Food and Drug Administration for the potential treatment of amyotrophic lateral sclerosis. Cytokinetics is also conducting non-clinical development of compounds that inhibit smooth muscle contractility and which may be useful as potential treatments for diseases and conditions associated with excessive smooth muscle contraction, such as systemic hypertension or bronchoconstriction. In addition, prior Cytokinetics' research generated three anti-cancer drug candidates that have progressed into clinical development: ispinesib, SB-743921 and GSK-923295. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations and the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Contact: [

Christopher S. Keenan

Director, Investor Relations and Media

(650) 624-3000

SOURCE: Cytokinetics, Inc.